Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sprint Nextel Corp. (NYSE: S), Ultrapar Participações SA (NYSE: UGP), Eurand N.V. (Nasdaq: EURX), Cephalon, Inc. (Nasdaq: CEPH) and GlaxoSmithKline Inc. (NYSE: GSK).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579
Here are highlights from Monday’s Analyst Blog:
Sprint Nextel Remains On Hold
Sprint Nextel (NYSE: S) is a leading provider of business and wireless communications services in the U.S. The company continues to experience lower revenue due to weakness in its wireless business and associated customer retention problems.
Lower subscriber count coupled with the management's cautious guidance reflects a disappointing outlook for the remainder of 2008 and early 2009. On a positive note, strong cash flow from operation along with favorable refinancing fostered encouraging balance sheet deleveraging as debt level was reduced. Also, Sprint recently launched its first 4G WiMAX wireless service and plans to rejuvenate its iDEN business.
Ultrapar SA Ultra-Attractive
We are changing our recommendation on Ultrapar Participações S.A. (NYSE: UGP) from Hold to Buy. Ultrapar posted positive results for the third quarter 2008. The short-term outlook for Oxiteno is now more positive due to lower oil prices, some depreciation on the Brazilian real, and the start of some operational expansions.
The Texaco deal is very positive, as it will help Ipiranga to serve its clients nationwide. Finally, we believe that Brazilian domestic consumption will be less affected by the current crisis. Thus, the current valuation seems attractive.
Eurand NV Strong with Zentase
Eurand N.V. (Nasdaq: EURX) is a specialty pharmaceutical company, engaging in the development, manufacture, and commercialization of enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies.
Strong anticipated sales of Zentase, in addition to the royalties on the sales of Cephalon's (Nasdaq: CEPH) Amrix and GlaxoSmithKline, Inc.'s (NYSE: GSK) EUR-1048 (to launch by year-end 2008), will drive the company to profitability in 2009 and beyond. We maintain our Buy rating with a price target of $14.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contacts:
Mark Vickery
Web Content Editor
312-265-9380
Visit:
www.zacks.com
